Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Sep. 2025,
Syn2bio paidzł0.00 Mil more to buy back shares than it received from issuing new shares.
It receivedzł0.00 Mil from issuing more debt.
It paidzł0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedzł0.00 Mil from paying cash dividends to shareholders.
It receivedzł21.38 Mil on other financial activities.
In all, Syn2bioearnedzł21.38 Mil on financial activities for the
six
months ended in Sep. 2025.
Syn2bio (WAR:S2B) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Syn2bio's issuance of stock for the
six
months ended in Sep. 2025 was zł0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Syn2bio's repurchase of stock for the
six
months ended in Sep. 2025 was zł0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Syn2bio's net issuance of debt for the
six
months ended in Sep. 2025 was zł0.00 Mil.
Syn2bio receivedzł0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Syn2bio's net issuance of preferred for the
six
months ended in Sep. 2025 was zł0.00 Mil.
Syn2bio paidzł0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Syn2bio's cash flow for dividends for the
six
months ended in Sep. 2025 was zł0.00 Mil.
Syn2bio receivedzł0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Syn2bio's other financing for the
six
months ended in Sep. 2025 was zł21.38 Mil.
Syn2bio receivedzł21.38 Mil on other financial activities.
Syn2bio Cash Flow from Financing Related Terms
Syn2bio Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Syn2bio's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Syn2bio's Cash from Financing for the fiscal year that ended in Sep. 2025 is calculated as:
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2025 was zł21.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of zł21.25 Mil mean?
Syn2bio (WAR:S2B) has a Cash Flow from Financing of zł21.25 Mil as of Sep. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Syn2bio and its competitors.
Is Syn2bio's Cash Flow from Financing too high?
Syn2bio's current Cash Flow from Financing is zł21.25 Mil. Overall, Syn2bio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's Cash Flow from Financing compare to VRTX and REGN?
Syn2bio's Cash Flow from Financing of zł21.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Syn2bio and its competitors. Syn2bio's current Cash Flow from Financing is zł21.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current Cash Flow from Financing of zł21.25 Mil. The current Cash Flow from Financing is zł21.25 Mil. Syn2bio's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current Cash Flow from Financing is zł21.25 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
9GF Score
Get the complete analysis for WAR:S2B
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:S2B has been successfully added to your 
